Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025)
Canopy Growth's (CGC) quarterly Income from Continuing Operations came in at 44908962.65 in Q4 2025, up 48.53% year-on-year from 30234842.93 in Q4 2024, and down 3670.84% quarter-over-quarter from 1190954.77 in Q3 2025.
Canopy Growth (CGC) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Canopy Growth has disclosed Income from Continuing Operations across 7 years of filings, most recently posting 44908962.65 for Q4 2025.
- Income from Continuing Operations for Q4 2025 came in at 44908962.65, up 48.53% year-over-year; the trailing twelve-month figure through Dec 2025 was 456064284.46 (up 330.29% YoY), and the FY2025 annual result was 265468727.16, up 227.28% from the prior year.
- Income from Continuing Operations came in at 44908962.65 for Q4 2025 at Canopy Growth, down from 1190954.77 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 532134756.83 in Q1 2025 to a low of 1640644562.36 in Q2 2022.
- The 5-year median for Income from Continuing Operations is 93041961.25 (2024), against an average of 146192651.12.
- Across the five-year window, Income from Continuing Operations sank 1100.5% in 2024 and jumped 564.23% in 2025, its largest moves.
- Canopy Growth's Income from Continuing Operations stood at 91627144.08 in 2021, then slumped by 82.39% to 167116641.72 in 2022, then declined by 1.21% to 169145903.03 in 2023, then soared by 48.41% to 87259146.83 in 2024, then surged by 48.53% to 44908962.65 in 2025.
- The last three Income from Continuing Operations figures came in at 44908962.65 (Q4 2025), 1190954.77 (Q3 2025), and 29970554.96 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | Canopy Growth | 11.38 Mn | -137.31 Mn | 15.39 Mn | -44.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -44.91 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -29.97 Mn |
| Mar 31, 2025 | 532.13 Mn |
| Dec 31, 2024 | -87.26 Mn |
| Sep 30, 2024 | -96.43 Mn |
| Jun 30, 2024 | -94.46 Mn |
| Mar 31, 2024 | 80.11 Mn |
| Dec 31, 2023 | -169.15 Mn |
| Sep 30, 2023 | -110.52 Mn |
| Jun 30, 2023 | -7.87 Mn |
| Mar 31, 2023 | -436.13 Mn |
| Dec 31, 2022 | -167.12 Mn |
| Sep 30, 2022 | -150.64 Mn |
| Jun 30, 2022 | -1.64 Bn |
| Mar 31, 2022 | -282.69 Mn |
| Dec 31, 2021 | -91.63 Mn |
| Sep 30, 2021 | -12.97 Mn |
| Jun 30, 2021 | 317.24 Mn |
| Mar 31, 2021 | -429.77 Mn |